The mitral valve has been an especially challenging target for transcatheter interventions, but there are reasons to think key breakthroughs are on the horizon. We talked to Kendra Grubb, MD, about this and other ongoing trends at TCT 2023. 

Kendra Grubb, MD, one of the country's leading experts on cardiac surgery, discussed what she tells her patients when they ask if TAVR is better than SAVR for treating severe aortic stenosis. 

Implanting the Barostim device is now associated with an average payment amount of $45,000, up significantly from the previous average of $29,000.

More than 100 U.S. medical societies are throwing their support behind a new proposal that could reform out-of-date Medicare policies and help limit future payment cuts. 

After 12 months, researchers found that the device was associated with control of AFib in 99% of patients and relief from AFib symptoms in 93.1% of patients.

IVUS was especially effective when treating patients with a complex coronary anatomy, researchers found. 

Could this late-breaking clinical trial from TCT 2023 be a sign of things to come in the years ahead? Samir Kapadia, MD, explored the topic in a new interview. 

CLAiR offers physicians another way to evaluate a patient’s cardiovascular health: non-invasive retinal images captured during routine eye exams.

Short-term mortality, however, does not appear to change when TAVR patients present with active cancer. 

Lawrence Faucette, the second patient to ever receive a genetically modified pig heart, died on Oct. 30. “He can never be forgotten," his wife said in a statement.